Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

BMC Psychiatry

Michael M Witte¹  Fangyi Zhao²  Holland C Detke² 

[1] Lilly USA, LLC, Indianapolis, IN, USA;Eli Lilly and Company, Indianapolis, IN, USA

关键词: Pharmacokinetics;    Onset;    Effect size;    Haloperidol;    Pamoate;    Long-acting injection;    Olanzapine;   

Others  :  1124380
DOI  :  10.1186/1471-244X-12-51

 received in 2011-10-24, accepted in 2012-05-30,  发布年份 2012

【 摘 要 】

Background

To treat acute schizophrenia, a long-acting injectable antipsychotic needs a rapid onset of action and therapeutic profile similar to that of oral agents. The present post-hoc analyses compared results from a randomized, double-blind, placebo-controlled trial of olanzapine long-acting injection (LAI) for acute schizophrenia with those observed in similarly designed trials of oral olanzapine.

Methods

Six-week results from the olanzapine LAI study (N = 404) were compared with those of 3 oral studies (study 1: olanzapine vs. haloperidol vs. placebo [N = 335]; study 2: olanzapine vs. haloperidol vs. low-dose olanzapine [N = 431]; study 3: olanzapine vs. placebo vs. low-dose olanzapine [N = 152]). All patients had baseline Brief Psychiatric Rating Scale (BPRS) scores ≥24 (0–6 scale). Six-week effect sizes were calculated. Efficacy onset, pharmacokinetics, discontinuations, weight gain, and extrapyramidal symptoms were also assessed.

Results

At 6 weeks, mean BPRS scores decreased by 14 to 15 points for olanzapine LAI (405 mg/4 weeks, 210 or 300 mg/2 weeks), by 8 to 16 for oral olanzapine (10 ± 2.5 or 15 ± 2.5 mg/day), and by 12 to 13 for haloperidol (15 ± 5 mg/day). For those same dose groups, effect sizes vs. placebo for the BPRS were 0.7 to 0.8 for olanzapine LAI, 0.5 to 0.7 for oral olanzapine, and 0.6 for haloperidol. The first statistically significant separation from placebo on the BPRS occurred at 3 days for the olanzapine LAI groups and at 1 week for oral olanzapine and haloperidol (15 ± 5 mg/day) in oral study 1 although as late as week 6 for the 10-mg/day olanzapine dose in oral study 3. Olanzapine concentrations were similar across studies. Weight gain ≥7% of baseline occurred in up to 35% of olanzapine LAI and oral patients versus up to 12% of haloperidol and placebo patients. Extrapyramidal symptoms were lowest in the olanzapine LAI groups and significantly greater in the haloperidol groups. No post-injection delirium/sedation syndrome events occurred in the olanzapine LAI study.

Conclusions

Patients treated acutely with olanzapine LAI showed a similar pattern of improvement to that seen historically with oral olanzapine. With the exception of injection-related adverse events, the efficacy and tolerability profile of olanzapine LAI is similar to oral olanzapine.

Trial registration

ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/ webcite: NCT00088478; ClinicalStudyResults.org ID; URL: http://www.clinicalstudyresults.org/ webcite: 917, 978, 982, and 5984.

【 授权许可】

   
2012 Detke et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010, 3:CD006654.
• [2]Ascher-Svanum H, Peng X, Faries D, Montgomery W, Haddad PM: Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry 2009, 9:46. BioMed Central Full Text
• [3]Glazer WM: The depot paradox. Behav Healthc 2007, 27:44-46.
• [4]Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006, 67:1948-1953.
• [5]Burns T: Knowledge about antipsychotic long-acting injections: bridging that gap. Br J Psychiatry Suppl 2009, 52:S5-S6.
• [6]Llorca PM: Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008, 161:235-247.
• [7]Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
• [8]West JC, Wilk JE, Olfson M, Rae DS, Marcus S, Narrow WE, Pincus HA, Regier DA: Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005, 56:283-291.
• [9]Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D: An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799.
• [10]Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167:181-189.
• [11]Frampton JE: Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs 2010, 70:2289-2313.
• [12]Lindenmayer J: Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat 2010, 6:261-267.
• [13]Naber D: Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother 2011, 12:627-633.
• [14]Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996, 14:111-123.
• [15]Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997, 7:125-137.
• [16]Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996, 124:159-167.
• [17]Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scan Suppl 1970, 212:11-19.
• [18]Barnes TR: A rating scale for drug induced akathisia. Br J Psychiatry 1989, 154:672-676.
• [19]Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care 1989, 27(3 Suppl):S178-S189.
• [20]McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, Sanchez-Felix MV, Sorsaburu S, Mitchell MI: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. II: investigations of mechanism. BMC Psychiatry 2010, 10:45. BioMed Central Full Text
• [21]McDonnell DP, Andersen SW, Detke HC, Zhao F, Watson SB: Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clinical Medicine Insights: Psychiatry 2011, 3:37-47.
• [22]Citrome L, Holt RI, Walker DJ, Hoffman VP: Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011, 31:455-482.
• [23]Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection. I: analysis of cases. BMC Psychiatry 2010, 10:43. BioMed Central Full Text
• [24]Kane JM, Leucht S: Unanswered questions in schizophrenia clinical trials. Schizophr Bull 2008, 34:302-309.
• [25]Masand PS, Roca M, Turner MS, Kane JM: Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009, 11:147-154.
• [26]Valenstein M, Ganoczy D, McCarthy JF, Myra KH, Lee TA, Blow FC: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006, 67:1542-1550.
• [27]Detke HC, Zhao F, Garhyan P, Carslon J, McDonnell D: Dose correspondence between olanzapine long-acting injection and oral olanzapine: reccomendations for switching. Int Clin Psychopharmacol 2011, 26:35-42.